{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:30:06Z","timestamp":1791351006275,"version":"4.3.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Leukemia and Lymphoma Society Career Development","award":["GC6840"],"award-info":[{"award-number":["GC6840"]}]},{"name":"National Comprehensive Cancer Center Young Investigator Award","award":["CA13873801"],"award-info":[{"award-number":["CA13873801"]}]},{"name":"The Damon Runyon Clinical Investigator Award","award":["GC3222"],"award-info":[{"award-number":["GC3222"]}]},{"name":"The Translational and Integrative Medicine Fund Research"},{"name":"The Annual Terry Fox Run for Cancer Research"},{"name":"Canada Club of New York","award":["GC7009"],"award-info":[{"award-number":["GC7009"]}]},{"name":"The Geoffrey Beene Cancer Foundation","award":["GC4035"],"award-info":[{"award-number":["GC4035"]}]},{"name":"The Bocina Cancer Research Fund","award":["GC7003"],"award-info":[{"award-number":["GC7003"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR0045"],"award-info":[{"award-number":["UL1TR0045"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jcyt.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T20:57:44Z","timestamp":1473454664000},"page":"1393-1409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells"],"prefix":"10.1016","volume":"18","author":[{"given":"Mark B.","family":"Geyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2016.07.003_bib0010","first-page":"277","article-title":"Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells","volume":"9","author":"Park","year":"2010","journal-title":"Discov Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0015","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","article-title":"CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells","volume":"3","author":"Davenport","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0025","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0030","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"Suppl.","key":"10.1016\/j.jcyt.2016.07.003_bib0045","article-title":"Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL","volume":"34","author":"Park","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V126.23.682.682","article-title":"Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL","volume":"126","author":"Park","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0060","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0065","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood.V126.23.3773.3773","article-title":"Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"},{"issue":"Suppl.","key":"10.1016\/j.jcyt.2016.07.003_bib0070","article-title":"Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r\/r) acute lymphoblastic leukemia (ALL)","volume":"34","author":"Frey","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0075","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse","volume":"131","author":"Gaynon","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0085","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1097\/MPH.0b013e318290c3d6","article-title":"Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group","volume":"35","author":"Reismuller","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0090","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0095","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0105","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.V126.23.2533.2533","article-title":"Multi-Center Clinical Trial of CAR T Cells in Pediatric\/Young Adult Patients with Relapsed B-Cell ALL","volume":"126","author":"Curran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0110","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood.V124.21.2296.2296","article-title":"Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells","volume":"124","author":"Frey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0115","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0130","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0135","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"Suppl.","key":"10.1016\/j.jcyt.2016.07.003_bib0140","article-title":"Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy","volume":"34","author":"Geyer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0145","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"Suppl.","key":"10.1016\/j.jcyt.2016.07.003_bib0160","article-title":"Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R\/R) CLL","volume":"34","author":"Porter","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0165","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0170","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0175","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0180","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0185","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas","volume":"126","author":"Schuster","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0190","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V126.23.184.184","article-title":"Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"},{"issue":"Suppl.","key":"10.1016\/j.jcyt.2016.07.003_bib0195","article-title":"Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel\/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)","volume":"33","author":"Sauter","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0200","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.V126.23.115.115","article-title":"CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets","volume":"126","author":"Danhof","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0215","series-title":"ASH Annual Meeting: Late-Breaking Abstracts","article-title":"Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor","author":"Ali","year":"2015"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0220","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","article-title":"Antibody targeting of B-cell maturation antigen on malignant plasma cells","volume":"6","author":"Ryan","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0225","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/jacs.5b01876","article-title":"An anti-B cell maturation antigen bispecific antibody for multiple myeloma","volume":"137","author":"Ramadoss","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0230","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0235","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0240","first-page":"4586","article-title":"Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII","volume":"55","author":"Weiner","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0245","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0250","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0255","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-08-0945","article-title":"A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity","volume":"8","author":"Feng","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0260","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0265","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0270","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable Remissions in Children with Relapsed\/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0275","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0280","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/ph8020230","article-title":"Seatbelts in CAR therapy: How Safe Are CARS?","volume":"8","author":"Minagawa","year":"2015","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0285","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.jcyt.2016.07.003_bib0290","article-title":"Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL","volume":"33","author":"Park","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0295","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0300","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","article-title":"Overcoming Antigen Escape with CAR T-cell Therapy","volume":"5","author":"Jackson","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0305","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2013-01-476606","article-title":"Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity","volume":"121","author":"Reiners","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0310","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0315","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"Gorgun","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0325","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0330","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","author":"Paggetti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0335","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0340","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0345","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/leu.2014.215","article-title":"IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia","volume":"29","author":"Pegram","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0350","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/nm1676","article-title":"T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0355","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0360","doi-asserted-by":"crossref","first-page":"e26286","DOI":"10.4161\/onci.26286","article-title":"Blockade of PD-1 immunosuppression boosts CAR T-cell therapy","volume":"2","author":"John","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0365","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2016.07.003_bib0370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324916304674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324916304674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:23:41Z","timestamp":1761431021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324916304674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1465324916304674"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2016.07.003","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society for Cellular Therapy.","name":"copyright","label":"Copyright"}]}}